Ultrasound evaluation of valsartan therapy for renal cortical perfusion

Hypertension Research

Volumn 27, Issue 5, 2004, Pages 345-349

  Kishimoto, Noriko ^a   Mori, Yasukiyo ^a   Nishiue, Takashi ^a   Nose, Atsuko ^a   Kijima, Yasuaki ^a   Tokoro, Toshiko ^a   Yamahara, Hideki ^a   Okigaki, Mitsuhiko ^a   Kosaki, Atsushi ^a   Iwasaka, Toshiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin antagonist; Regional blood flow; Renal circulation; Renal disease; Ultrasonography

Indexed keywords

4 AMINOHIPPURIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CONTRAST MEDIUM; VALSARTAN;

4 AMINOHIPPURIC ACID CLEARANCE; ACCURACY; ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VOLUME; CALCULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; ECHOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGING SYSTEM; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY PERFUSION; MALE; NORMAL HUMAN; OPTIMAL DRUG DOSE; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADULT; AIR; FEMALE; HUMANS; IMAGE ENHANCEMENT; KIDNEY CORTEX; MALE; MICROSPHERES; RECEPTORS, ANGIOTENSIN; RENAL CIRCULATION; TETRAZOLES; VALINE;

EID: 3042593786     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.345     Document Type: Article

References (24)

1. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S: Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998; 97: 473-483.
2. Rim SJ, Leong-Poi H, Lindner JR, et al: Quantification of cerebral perfusion with "real-time" contrast-enhanced ultrasound. Circulation 2001; 104: 2582-2587.
3. Wei K, Le E, Bin JP, Coggins M, Thorpe J, Kaul S: Quantification of renal blood flow with contrast-enhanced ultrasound. J Am Coll Cardiol 2001; 37: 1135-1140.
4. Hosotani Y, Takahashi N, Kiyomoto H, et al: A new method for evaluation of split renal cortical blood flow with contrast echography. Hypertens Res 2002; 25: 77-83.
5. Kishimoto N, Mori Y, Nishiue T, et al: Renal blood flow measurement with contrast-enhanced harmonic ultrasonography: evaluation of dopamine-induced changes in renal cortical perfusion in humans. Clin Nephrol 2003; 59: 423-428.
6. Cosgrove D, Eckersley R, Blomley M, Harvey C: Quantification of blood flow. Eur Radiol 2001; 11: 1338-1344.
7. Yura T, Yuasa S, Fukunaga M, Badr KF, Matsuo H: Role for Doppler ultrasound in the assessment of renal circulation: effects of dopamine and dobutamine on renal hemodynamics in humans. Nephron 1995; 71: 168-175.
8. Gilman A, Phillips FS, Koelle ES: The renal clearance of thiosulfate with observations on its volume distribution. Am J Physiol 1946; 146: 348-357.
9. Criscione L, Bradley WA, Buehlmayer P, et al: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13: 230-250.
10. Hollenberg NK: AT1-receptor blockade and the kidney: importance of non-ACE pathways in health and disease. J Hum Hypertens 2002; 16: S59-S63.
11. No author listed: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy: the GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 28: 1857-1863.
12. Weinberg MS, Weinberg AJ, Cord R, Zappe DH: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS 2001; 2: S196-S198.
13. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T: Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003; 46: 413-419.
14. Apperloo AJ, de Zeeuw D, de Jong PE: A short-term anti-hypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793-797.
15. Mizuno M, Sada T, Kato M, Koike H: Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271-278.
16. Buter H, Navis G, de Zeeuw D, de Jong PE: Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. Kidney Int 1997; 43 (Suppl): 185-187.
17. 15O. J Nucl Med 2002; 43: 470-475.
18. Nagao M, Murase K, Saeki H, et al: Pulsating renal blood flow distribution measured using power Doppler ultrasound: correlation with hypertension. Hypertens Res 2002; 25: 697-701.
19. Lansang MC, Osei SY, Price DA, Fisher ND, Hollenberg NK: Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 2000; 36: 834-838.
20. Conlin PR, Spence JD, Williams B, et al: Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
21. Corea L, Cardoni O, Fogari R, et al: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341-346.
22. Murayama S, Hirano T, Sakue T, Okada K, Ikejiri R, Adachi M: Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003; 26: 453-458.
23. Taniguchi M, Kim S, Zhan Y, Iwao H: Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. Hypertens Res 2002; 25: 287-294.
24. Thaiss F, Haas C, Helmchen U, Wenzel U, Stahl RA: Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology. Nephrol Dial Transplant 1996; 11: 40-46.